BACKGROUND: Neurofilaments are the major cytoskeletal components of neurons, and cell injury leads to their release into the surrounding area. The aim of this study was to compare the cerebrospinal fluid (CSF) and serum (S) concentrations of neurofilament light chains (NFLs) and phosphorylated neurofilament heavy chains (pNFHs). METHODS: Neurofilament concentrations were measured in CSF and S samples from 172 patients using three enzyme-linked immunosorbent assays. Excel, Stata version 13, MedCal version 17.9.7., and NCSS 2007 software were used for the statistical analysis. RESULTS: There was a statistically significant correlation between the concentrations of CSF NFL and CSF pNFH (rs = 0.748; n = 89; P < 0.001), but Passing-Bablok regression showed systematic deviation between the values obtained using the two assays. This indicates that the assays were not interchangeable. CSF pNFH and S pNFH concentrations showed low correlation. The kappa statistic showed moderate conformity between CSF pNFH and CSF NFL concentrations (κ = 0.556). CONCLUSIONS: The CSF NFL and CSF pNFH assays gave clinically consistent results that reflected the degree of axonal damage, independent of any particular neurological diagnosis. The S pNFH assays had a lower predictive value due to the low correlation coefficient and the kappa index of the CSF pNFH method.

Clinic of Neurology University Hospital Ostrava Ostrava Czech Republic

Department of Clinical Biochemistry Institute of Laboratory Diagnostics University Hospital Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Grant P, Pant HC. Neurofilament protein synthesis and phosphorylation. J. Neurocytol. 2000;29:843‐872. PubMed

Slawson C, Hart GW. Dynamic interplay between O‐GlcNAc and O‐phosphate: the sweet side of protein regulation. Curr Opin Struct Biol. 2003;13(5):631‐636. PubMed

Kuhle J, Barro C, Disanto G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. 2016;22(12):1550‐1559. PubMed

Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233(1‐2):183‐198. PubMed

Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206‐1213. PubMed

Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010;16(3):287‐292. PubMed

Khalil M, Enzinger C, Langkammer C, et al. CSF neurofilament and N‐acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2013;19(4):436‐442. PubMed PMC

Martinez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550‐561. PubMed PMC

Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18(5):552‐556. PubMed

Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69(1):83‐89. PubMed

Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014;20(1):43‐50. PubMed

Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing‐remitting multiple sclerosis. Neurology. 2015;84(16):1639‐1643. PubMed PMC

Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand. 2007;116(2):100‐107. PubMed

Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pitha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol. 2007;254(1):20‐25. PubMed

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162‐173. PubMed

Neurofilament (pNf‐H) ELISA, Euroimmun Medizinische Labordiagnostika AG (Germany). Version: 20/07/2017.

McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica. 2012;22(3):276‐282. PubMed PMC

Arrambide G, Espejo C, Eixarch H, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016;87(11):1076‐1084. PubMed PMC

Stata Version 13. Stata Press Publication, Texas, 2013. ISBN‐13:978‐1‐59718‐129‐7.

Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci. 1996;19:187‐217. PubMed

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Ǻ. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence assay and Simoa. Clin Chem Lab Med. 2016;54(10):1655–1661. PubMed

De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis . J Neurol Neurosurg Psychiatry. 2018;89(4):367‐373. PubMed

Lu CH, Kalmar B, Malaspina A, Greensmith L, Petzold A. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods. 2011;195:143‐150. PubMed

Mariotto S, Farinazzo A, Monaco S, et al. Neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin‐4 and myelin oligodendrocyte glycoprotein antibodies status. Mult Scler J Exp Transl Clin. 2017;3(4):2055217317743098. PubMed PMC

Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016;87(2):126‐129. PubMed

Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25(5):678‐686. PubMed

Diagnostic utility of neurofilament markers for MND is limited in restricted disease phenotype and for differentiation from compressive myeloradiculopathies

Can Aspartate Aminotransferase in the Cerebrospinal Fluid Be a Reliable Predictive Parameter?